Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pioglitazone.

P S Gillies1, C J Dunn

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Drugs
|September 13, 2000
PubMed
Summary
This summary is machine-generated.

Pioglitazone effectively lowers blood glycosylated hemoglobin (HbA1c) and fasting blood glucose in type 2 diabetes patients. This insulin sensitizer improves glycemic control and lipid profiles with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet.

European journal of hybrid imaging·2022
Same author

Bisphosphonates: a review of their novel anti-inflammatory properties and potential for the treatment of rheumatoid arthritis.

IDrugs : the investigational drugs journal·2008
Same author

Recombinant Factor VIIa.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Study on spontaneous cerebrospinal fluid rhinorrhoea: its aetiology and management.

The Journal of laryngology and otology·2005
Same author

Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same author

Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis.

International journal of immunopharmacology·2003
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Pioglitazone is a thiazolidinedione agent for type 2 diabetes.
  • It activates peroxisome proliferator activated receptor-gamma (PPAR-gamma).
  • PPAR-gamma activation enhances insulin sensitivity in liver and peripheral tissues.

Purpose of the Study:

  • To evaluate the efficacy of pioglitazone in managing type 2 diabetes mellitus.
  • To assess its impact on glycemic control and lipid profiles.
  • To determine its tolerability and safety profile.

Main Methods:

  • Placebo-controlled clinical trials were conducted.
  • Pioglitazone was administered as monotherapy (15-45 mg/day).
  • Pioglitazone was also studied in combination with metformin, sulfonylurea, insulin, or voglibose.

Related Experiment Videos

Main Results:

  • Pioglitazone monotherapy significantly reduced HbA1c levels.
  • Combination therapy with pioglitazone decreased HbA1c and fasting blood glucose.
  • Improvements in serum lipid profiles were observed.
  • The drug was well tolerated, with edema and hypoglycemia as reported side effects.

Conclusions:

  • Pioglitazone is an effective treatment for type 2 diabetes, improving glycemic control.
  • It offers benefits in lipid metabolism and is generally well-tolerated.
  • No hepatotoxicity was reported in clinical studies.